$Meta Platforms, Inc.(META)$ also stands out. Its huge user base and advertising business give it multiple ways to monetize AI investments. The $820 target is aggressive, but stronger AI adoption could justify higher expectations.
I am more cautious on $Novo-Nordisk A/S(NVO)$ . The semaglutide concentration risk is real, but I would not write off the company yet. Overall, Wall Street looks increasingly selective, and I prefer focusing on improving fundamentals rather than simply following upgrades.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- littlesweetie·09-15 23:43TOPThat 355 target already assumes near-perfect execution. NBIS trading at a rich premium means even one contract slip can force a nasty rerating lol1Report
- 1PC·09-15 23:20TOPNice Sharing 😁 @Aqa @DiAngel @Barcode @JC888 @koolgal @Shernice軒嬣 20001Report